Article thumbnail

Intranasal ciclesonide for allergic rhinitis

By Ben Williams, William B Smith and Frank E Kette


Ciclesonide is a novel corticosteroid which is optimized for topical use. It is a pro-drug which is activated locally in the airway mucosa, lipid-conjugated for local retention, and has very high protein binding in circulation leading to low systemic bioavailability. These characteristics should lead to highly selective activity with reduced local and systemic side effects. It has been established as an inhaled medication for asthma and has also been shown in double-blind trials to be efficacious for the treatment of seasonal and perennial allergic rhinitis. However no data have yet demonstrated superiority over existing nasal topical corticosteroids, either in terms of efficacy or adverse effects, and trials have not yet clearly shown efficacy in rhinitis in children. Therefore the place of ciclesonide in the treatment of allergic rhinitis relative to other existing products remains unclear

Topics: Review
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2003). A comparison of nasal clearance after treatment of perennial allergic rhinitis with budesonide and mometasone. Otolaryngol Head Neck Surg,
  2. (1998). Assessment by nasal biopsy of long-term use of mometasone furoate aqueous nasal spray (Nasonex) in the treatment of perennial rhinitis. Otolaryngol Head Neck Surg,
  3. (2008). Assessment of the long-term safety of inhaled ciclesonide on growth in children with asthma.
  4. (2001). Benzalkonium chloride as a preservative in nasal solutions: re-examining the data.
  5. (2007). Ciclesonide and beclomethasone dipropionate coadministration: effect on cortisol in perennial allergic rhinitis.
  6. (2000). Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate.
  7. (2006). Effectiveness of ciclesonide nasal spray in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol,
  8. (1995). Effects of formulation variables on nasal epithelial cell integrity: biochemical evaluations.
  9. (1998). Effects of intranasal corticosteroids on adrenal, bone, and blood markers of systemic activity in allergic rhinitis.
  10. (2007). Effi cacy and safety of ciclesonide, 200 microg once daily, for the treatment of perennial allergic rhinitis. Ann Allergy Asthma Immunol,
  11. (2005). Formation of fatty acid conjugates of ciclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide.
  12. (2007). Formulation considerations of intranasal corticosteroids for the treatment of allergic rhinitis.
  13. (2004). In vitro and in vivo anti-infl ammatory activity of the new glucocorticoid ciclesonide.
  14. (2004). Infl uence of preservatives and topical steroids on ciliary beat frequency in vitro. Arch Otolaryngol Head Neck Surg,
  15. (2007). Intranasal ciclesonide coadministration with inhaled fluticasone propionate-salmeterol does not suppress cortisol in allergic rhinitis patients.
  16. (1998). Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials.
  17. (2003). Intranasal steroid sprays in the treatment of rhinitis: is one better than another?
  18. (2007). Long-term safety and effi cacy of intranasal ciclesonide in adult and adolescent patients with perennial allergic rhinitis. Ann Allergy Asthma Immunol,
  19. (1988). Long-term safety of budesonide nasal aerosol: a 5.5-year follow-up study.
  20. (2004). Nasal toxicity of benzalkonium chloride.
  21. (2007). Once-daily administration of intranasal corticosteroids for allergic rhinitis: a comparative review of effi cacy, safety, patient preference, and cost.
  22. (2006). Once-daily ciclesonide in children: effi cacy and safety in asthma.
  23. (2002). Patient preferences and sensory comparisons of three intranasal corticosteroids for the treatment of allergic rhinitis.
  24. (2004). Patient preferences for sensory attributes of intranasal corticosteroids and willingness to adhere to prescribed therapy for allergic rhinitis: a conjoint analysis. Ann Allergy Asthma Immunol,
  25. (2005). Preclinical profi le of ciclesonide, a novel corticosteroid for the treatment of asthma.
  26. (2005). Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, ciclesonide.
  27. (2004). Safety review of benzalkonium chloride used as a preservative in intranasal solutions: an overview of confl icting data and opinions. Otolaryngol Head Neck Surg,
  28. (2006). Safety, tolerability, and exposure of ciclesonide nasal spray in healthy and asymptomatic subjects with seasonal allergic rhinitis.
  29. (2006). Short course of systemic corticosteroids in sinonasal polyposis: a double-blind, randomized, placebo-controlled trial with evaluation of outcome measures.
  30. (1994). Temporary inhibition of growth and adrenal suppression associated with the use of steroid nose drops.
  31. (1999). The new topical steroid ciclesonide is effective in the treatment of allergic rhinitis.
  32. (2003). Two multicenter, randomized, single-blind, single-dose, crossover studies of specifi c sensory attributes of budesonide aqueous nasal spray and fl uticasone propionate nasal spray.